Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of Damiano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damiano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damiano more than expected).
This network shows the impact of papers produced by Damiano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damiano. The network helps show where Damiano may publish in the future.
Co-authorship network of co-authors of Damiano
This figure shows the co-authorship network connecting the top 25 collaborators of Damiano.
A scholar is included among the top collaborators of Damiano based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Damiano. Damiano is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
11 of 11 papers shown
1.
Paolo, Giovanni Giovanni, �� Lá, et al.. (2016). L.ong-term recovery of normal sexual function in lesticular cancer survivors. 亚洲男性学杂志：英文版. 85–89.8 indexed citations
Bianco, Roberto, Roberta Rosa, Damiano, et al.. (2008). VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells.. 14. 5069–5080.
4.
Damiano, et al.. (2004). Verification: What works and what doesn't. Design Automation Conference.1 indexed citations
5.
Ciardiello, Fortunato, Roberto Bianco, R. Caputo, et al.. (2003). Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs.. Journal of Clinical Oncology. 2003. 820–821.6 indexed citations
6.
Tortora, Giampaolo, R. Caputo, Damiano, et al.. (2003). Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity. 866–871.3 indexed citations
7.
Tortora, Giampaolo, R. Caputo, Damiano, et al.. (2003). Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect. 1231–1232.2 indexed citations
Ciardiello, Fortunato, R. Caputo, Roberto Bianco, et al.. (2000). Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor.. 6. 2053–2063.19 indexed citations
Ciardiello, Fortunato, Damiano, Gabriella Fontanini, et al.. (2000). Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells.. 6. 3739–3747.4 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.